Immune Checkpoint Patient Stratification: A Central Laboratory Perspective

Get in Touch

Our Locations

Immune Checkpoint Patient Stratification: A Central Laboratory Perspective

DIA China 2018 lecture

This presentation provides an overview of trends in immuno-oncology studies targeting PD-1 and PD-L1, and discusses recruitment for immune checkpoint inhibitor trials, and provides challenges and insights. This was presented by Q² Solutions at the DIA China 2018 conference.

Download this presentation to learn more.

Speaker:
Patrice Hugo, PhD, Chief Scientific Officer

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

A new ELISpot/FluoroSpot best practice using a novel lyophilized FBS for clinical immune monitoring assays

Interferon gamma (IFN) ELISpot and FluoroSpot are widely used immune monitoring assays to detect functional cell responses in clinical studies. Recognized for their importance in vaccine development...

Podcast

What is the Role of Digital Pathology in Clinical Trials

In this episode, Dr. Monika Lamba, a pathologist from Q² Solutions, discusses the transformative role of digital pathology in clinical trials. Despite its origins aiming to streamline trials, it's...

Brochure

Vaccine Laboratory Services

With emerging and re-emerging infectious diseases, the development of new anti-infectives and vaccines presents many challenges. Q² Solutions understands these challenges in vaccine development. Our...